Abhinav A. Shukla, who serves as Chief Technical Officer at Shattuck Labs, Inc., recently executed a sale of company shares. On May 12, 2026, Mr. Shukla disposed of 2,032 shares of the firm's common stock. The transaction saw the shares sold at a weighted average price of $7.01 per share. Individual sales within this block ranged from $7.00 to $7.02 per share, resulting in total proceeds valued at $14,244.
This recent selling activity takes place against a backdrop of significant market movement for Shattuck Labs stock. According to InvestingPro data, the company's stock has appreciated by 574% over the past twelve months. Despite this substantial upward trend, the current trading price is reported at $6.67, which sits below the weighted average sale price observed in Mr. Shukla’s transaction.
Financial metrics also provide context for the valuation. With a market capitalization of $500 million, InvestingPro analysis suggests that the stock may currently be overvalued when measured against its calculated Fair Value.
Transaction Mechanics and Holdings
The sale was not an open-market trade but rather executed under the framework of a Rule 10b5-1 trading plan. Mr. Shukla initiated this specific plan on February 2, 2026. The stated purpose of the Rule 10b5-1 plan is to facilitate the execution of sales related to shares received through option exercises, primarily intended to cover both the exercise price and the estimated tax withholding associated with those same option exercises.
Prior to conducting this sale, Mr. Shukla had acquired an additional 2,032 shares of Shattuck Labs common stock. These shares were obtained through the exercise of stock options at a cost of $3.57 per share, totaling $7,254 in value for that acquisition. Following these transactions, his current holdings include 81,258 shares of Shattuck Labs common stock directly held by him. Furthermore, he maintains an additional position consisting of 50,168 unexercised stock options.
Positive Industry Developments and Analyst Coverage
Separately, the company has received positive commentary from investment analysts. TD Cowen recently reiterated a Buy rating for Shattuck Labs. This decision to maintain a favorable rating was based on an assessment of SL-325, which is identified as the firm's lead drug candidate. The compound itself is described as an anti-DR3 monoclonal antibody designed with the objective of blocking the DR3-TL1A axis.
The positive outlook from TD Cowen has been bolstered by recent toxicology studies conducted in non-human primates. These trials demonstrated a favorable safety profile for SL-325. Specifically, the studies indicated complete and durable receptor occupancy that persisted for two to four weeks. Crucially, this level of occupancy was achieved at or below the no-observed-adverse-effect level of 100 mg/kg. These scientific findings are cited as contributing factors to the continued positive assessment from TD Cowen.
The analysis of executive trading activity alongside clinical development milestones provides a comprehensive view of internal confidence and external validation for Shattuck Labs, Inc.